Associated Papers
Novel therapeutic strategies for rare mutations in non-small cell lung cancer.
Gou Q et al.
Scientific Reports, 2024
EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.
Elshatlawy M et al.
Molecular Oncology, 2023
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046.
Repetto M et al.
Investigational New Drugs, 2022
Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.
Koga T et al.
Cancer Science, 2022
Will the clinical development of 4th-generation "double mutant active" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?
Ou SI et al.
Translational Oncology, 2021
NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.
Sánchez-Herrero E et al.
Molecular Oncology, 2021
34058070 (PubMed )
Supplement: MOL2-15-2363-s001.docx
Computational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation.
Patil K et al.
Proceedings of the National Academy of Sciences of the United States of America, 2021
Targeting anaplastic lymphoma kinase in neuroblastoma.
Umapathy G et al.
Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica, 2019
Resistance to molecularly targeted therapy in non-small-cell lung cancer.
Asao T et al.
Respiratory Investigation, 2019
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Zhang S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
27780853 (PubMed )
Supplement: 10780432ccr160569-sup-163226_2_supp_3574910_tdyq9n.pdf
Select a paper to view details